Qishenyiqi Dripping Pill for Coronary Microvascular Disease

The Efficacy and Safety of Qishenyiqi Dripping Pill in Patients With Coronary Microvascular Disease

To investigate the efficacy and safety of Qishenyiqi in patients with microvascular angina pectoris. Long-term follow-up of 1 year will be performed to evaluate the effect of Qishenyiqi on coronary flow reserve and adverse cardiovascular events in patients with coronary microvascular disease.

Inclusion Criteria:

• Repeated chest pain attacks with typical exertional angina pectoris or resting angina pectoris attacks;
• Coronary normal or stenosis < 20%;
• Ischemic depression in ST segment during resting or exercise;
• Blood flow reserve (CFR) of the anterior descending coronary artery < 2.0;
• Subjects or their guardians agreed to participate in this study.

Exclusion Criteria:

• Previous myocardial infarction or PCI or CABG treatment;
• A history of heart failure;
• Severe arrhythmia;
• Refractory hypertension or hypertension accompanied by left ventricular wall thickness > 12 mm;
• Familial hypercholesterolemia;
• Takayasu arteritis, Kawasaki disease or coronary artery malformation;
• Pregnant or nursing, or having the intention to give birth within one year;
• Hepatic or renal dysfunction;
• Allergic to contrast agents or traditional Chinese medicines;
• Patients who participated in clinical research of other drugs within 3 months before being selected.